Previous 10 | Next 10 |
Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.25 and the consensus Revenue Estimate is $2.45M For further details see: Pieris Pharmaceuticals Q4 2021 Earnings Preview
ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, tod...
TUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christophe...
COVID-19 has dominated the healthcare space for a couple of years now. Indeed, it's been the dominant concern for most of the world. It has also produced some exciting investing opportunities. But there are outstanding opportunities outside of COVID, too. Three Fool.com contributors have fo...
Growth stocks, on balance, have fallen out of favor in recent months. Political gridlock in Washington, D.C., historically high inflation rates, and concerns about an interest rate increase have dampened investors' appetite for risk. This negative sentiment, though, doesn't mean there aren'...
BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today a...
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today an...
BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, to...
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other ind...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-17 02:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
2024-07-07 05:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...